

Supporting information

Tumor-homing glycol chitosan-based optical/PET dual imaging nanoprobe for cancer diagnosis

Sangmin Lee^{†,Δ}, Sun-Woong Kang^{‡,Δ}, Ju Hee Ryu[†], Jin Hee Na[†], Dong-Eun Lee[§], Seung Jin Han[†], Choong Mo Kang^{||}, Yearn Seong Choe^{||}, Kyo Chul Lee[#], James F. Leary[⊥], Kuiwon Choi[†], Kyung-Han Lee^{||,*} and Kwangmeyung Kim^{†,*}

[†]Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea

[‡]Next-generation Pharmaceutical Research Center, Korea Institute of Toxicology, Daejeon, Republic of Korea

[§]Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeonbuk, Republic of Korea

^{||} Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

[#]Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea

[⊥]Departments of Pharmaceutics and Biomedical Engineering, Purdue University, IN 47907, USA

A

MMP substrate peptide

(NH₂-Gly-Pro-Leu-Gly-Val-Arg(pbf)-Gly-Lys(Boc)-Gly-Gly-COOH)



Cy5.5-MMP substrate peptide

(**Cy5.5**-Gly-Pro-Leu-Gly-Val-Arg(pbf)-Gly-Lys(Boc)-Gly-Gly-COOH)



Activatable MMP probe (AMP)

(**Cy5.5**-Gly-Pro-Leu-Gly-Val-Arg-Gly-Lys-Gly-Gly-COOH)



AMP-DBCO

(**Cy5.5**-Gly-Pro-Leu-Gly-Val-Arg-Gly-Lys-Gly-Gly-PEG₄-**DBCO**)

BHQ-3

BHQ-3

B




Figure S1. (A) Scheme for synthesis of AMP-DBCO. (B) HPLC profiles of the reaction mixture for creating the AMP-DBCO.




Figure S2. (A) Representative wound healing images of MCF-7, MDA-MB-231, and A549 at 24 h. The black dotted lines indicate at 0 h. (B) The percentage of wound healing in (A). (C) NIR fluorescence image of MMP-sensitive probe in culture medium of MCF-7, MDA-MB-231, and A549, and quantitative data.